Form 4: MapLight Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics, Inc., reported multiple transactions in common stock on August 17, 2026.
Summary
- Grant/award: acquired 6,020 Voting Common Stock on August 17, 2026; holds 180,926 after (Direct).
- Grant/award: acquired 24,455 Employee Stock Option (right to buy) on August 17, 2026; holds 24,455 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Anatol Kreitzer — Officer (Chief Discovery Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Grant/award | Voting Common Stock | 6,020 | — | — | 180,926 |
| 2026-08-17 | Grant/award | Employee Stock Option (right to buy) | 24,455 | — | — | 24,455 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Grant/award (6,020 shares) |
| 2026-08-17 | Grant/award (24,455 shares) |
Keywords
insider transaction, Form 4, MPLT, MapLight Therapeutics, Inc., neutral, Anatol Kreitzer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.